COGT - NASDAQ
Cogent Biosciences, Inc.
$32.26
+0.19%Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotCogent Biosciences, Inc. Profit Bridge
Profitability Analysis
Cogent Biosciences, Inc. Income Statement
COGT • NASDAQ
| Cogent Biosciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.9M | 22.5M | 9.7M | 8.4M | 6.4M | 3M | |
GROSS PROFIT | |||||||||||
(4.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (25.7M) | (43.7K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-4.6M | 0.0 | 0.0 | 0.0 | 0.0 | -17.9M | 22.5M | 9.7M | 8.4M | 6.4M | 3M | |
OPERATING INCOME | |||||||||||
(328.7M) | (275.9M) | (208.1M) | (147.8M) | (75.6M) | (64.3M) | (54.7M) | (45.7M) | (34.5M) | (25.4M) | (9.6M) | |
(63.6M) | (43.3M) | (34.4M) | (26.2M) | (19.6M) | (17.4M) | (11M) | (7.5M) | (4.7M) | (3.4M) | (2.7M) | |
(269.8M) | (232.7M) | (173.8M) | (121.6M) | (55.9M) | (72.6M) | (43.7M) | (38.3M) | (29.8M) | (22M) | (6.9M) | |
-333.4M | -275.9M | -208.1M | -147.8M | -75.6M | -82.2M | -32.2M | -36M | -26.2M | -19.1M | -6.6M | |
PRE-TAX INCOME | |||||||||||
(3.1M) | (0.0) | (0.0) | (4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
11.6M | 18.1M | 13.1M | 0.0 | 467K | 144K | 267K | 1.2M | 386K | 265K | 0.0 | |
-4.6M | (0.0) | (0.0) | (0.0) | (0.0) | -25.7M | (78K) | (320K) | (274K) | (0.0) | (0.0) | |
4.4M | 20.1M | 15.7M | 7.6M | 3.3M | 7.4M | 345K | 1.5M | 660K | 946K | 0.0 | |
-328.9M | -255.9M | -192.4M | -140.2M | -72.3M | -74.8M | -31.8M | -34.5M | -25.5M | -18.1M | -6.6M | |
NET INCOME | |||||||||||
-328.9M | -255.9M | -192.4M | -140.2M | -72.3M | -74.8M | -30.3M | -34.5M | -25.5M | -18.1M | -6.6M |
SEC Filings
COGT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 18, 2025 | November 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your COGT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.